Axsome released their fourth quarter financial results today. Just a few highlights from the just completed impressive quarter, are below.
- Auvelity for MDD sales totaled $49.0 million for the quarter
- Sunosi for narcolepsy sales totaled $22.5 million for the quarter
- $386 million in cash on hand, end of quarter
- AXS-12 clinical trial for cataplexy, to read out in the first quarter, 2024
- AXS-05 clinical trial for Alzheimer's Disease Agitation, second half 2024
The only negative seen for this quarterly release is the clinical trial of AXS-05 for Alzheimer's Disease Agitation, which has been moved to be released in the second half of 2024. Current chart of Axsome below. Thank you for reading.
No comments:
Post a Comment